Advisory Council on the Misuse of Drugs. (2012) ACMD Methoxetamine report. London: Home Office.
Preview | Title | Contact |
---|---|---|
![]()
|
PDF (methoxetamine report)
- Published Version
437kB |
Report from the ACMD to the UK Home Secretary about methoxetamine.
The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well-documented and serious adverse effects following both acute and chronic usage.
Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations.
The ACMD considers, from the available evidence, that the harms of methoxetamine are commensurate with Class B, of the UK Misuse of Drugs Act (1971); and it should be scheduled under Schedule I of the Misuse of Drugs Regulations (2001) (having no known recognised medicinal use).
Repository Staff Only: item control page